Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: a pilot study.

[1]  Daniel W. Miller,et al.  Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. , 2005, JAMA.

[2]  C. N. Coleman,et al.  Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy. , 2005, International journal of radiation oncology, biology, physics.

[3]  Jeff M Michalski,et al.  Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. , 2005, International journal of radiation oncology, biology, physics.

[4]  G. Matsopoulos,et al.  Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application. , 2005, International journal of radiation oncology, biology, physics.

[5]  G. Matsopoulos,et al.  A Phase II Randomized Study of Topical Intrarectal Administration of Amifostine for the Prevention of Acute Radiation-Induced Rectal Toxicity , 2004, Strahlentherapie und Onkologie.

[6]  Richard K Valicenti,et al.  Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. , 2004, International journal of radiation oncology, biology, physics.

[7]  G. Matsopoulos,et al.  Amifostine as Radioprotective Agent for the Rectal Mucosa during Irradiation of Pelvic Tumors , 2003, Strahlentherapie und Onkologie.

[8]  G. Calais,et al.  Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. , 2002, Seminars in oncology.

[9]  George Starkschall,et al.  Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. , 2002, International journal of radiation oncology, biology, physics.

[10]  I. Kaplan,et al.  A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury. , 2002, International journal of radiation oncology, biology, physics.

[11]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[12]  H M Sandler,et al.  Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. , 2000, Urology.

[13]  V. Georgoulias,et al.  Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Pötter,et al.  Endoscopic scoring of late rectal mucosal damage after conformal radiotherapy for prostatic carcinoma. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  F. Prott,et al.  Amifostine: a radioprotector in locally advanced head and neck tumors. , 1998, Oncology reports.

[16]  L. Shaw,et al.  Topical application of WR-2721 achieves high concentrations in the rectal wall. , 1995, Radiation research.

[17]  J. Delaney,et al.  Radioprotection of the rat small intestine with topical WR‐2721 , 1994, Cancer.

[18]  M. Kligerman,et al.  Interim analysis of a randomized trial of radiation therapy of rectal cancer with/without WR-2721. , 1992, International journal of radiation oncology, biology, physics.

[19]  M. Schell,et al.  Intraoperative radiotherapy with localized radioprotection: diminished duodenal toxicity with intraluminal WR2721. , 1991, International journal of radiation oncology, biology, physics.

[20]  R. Jirtle,et al.  Intracolonic WR 2721 protection of the rat colon from acute radiation injury. , 1986, Gastroenterology.

[21]  F. Stewart,et al.  Radioprotection of two mouse tumors by WR-2721 in single and fractionated treatments. , 1983, International journal of radiation oncology, biology, physics.

[22]  P. Kuna.  Duration and degree of radioprotection of WR-2721 in mice following its intraperitoneal, intramuscular and subcutaneous administration. , 1983, Radiobiologia, radiotherapia.

[23]  A. D. Conger,et al.  Radioprotection by WR-2721 against long-term chronic damage to the rat parotid gland. , 1978, Radiation research.

[24]  J. Utley,et al.  Radioprotection of oral cavity structures by WR-2721. , 1978, International journal of radiation oncology, biology, physics.